Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jared Weiss is an Associate Professor of Clinical Research for Hematology/Oncology at the University of North Carolina School of Medicine in Chapel Hill, NC. He completed fellowship in Hematology and Oncology at the University of Pennsylvania and residency in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, MA. He received his Doctor of Medicine at Yale University School of Medicine in New Haven, CT and his B.S. in neuroscience at Brown University, in Providence, RI.

Lung Cancer Video Library - Trends in Lung Cancer Demographics and Changes in Histology
Fri, 03/11/2016 - 14:51
Lung Cancer Video Library
Author
Jared Weiss, MD, Faculty and Board Vice President

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, speaks about details in the trends in lung cancer demographics and changes in histology by race and gender.


Transcript

I will speak to you today about trends in lung cancer demographics. So the incidence is probably the most important trend that we’ve had over the years, and this is somewhat different by men and women.

GCVL_LU-A02b_LC_Demographics__Histology_02

Amongst men you can see that we’ve had a nice decline in cancers of the lung, perhaps not as great as we would like but a very real decline. In contrast, amongst women we had an increase in incidence over the years that has finally leveled off and is beginning to hopefully decline.

GCVL_LU-A02b_LC_Demographics__Histology_04

There have been some trends in decreased incidence and [improved] survival — these are usually looked at by five year survival rates and unfortunately because of the high morbidity, high mortality, of lung cancer, these rates have not improved as much as some of the other cancers here, but you can see there has been a real, if small decline. This effect has been more pronounced among whites than amongst other minority groups.

GCVL_LU-A02b_LC_Demographics__Histology_05

We have had a change in histology over time — histology is the type of lung cancer. When we’ve spoken in other podcasts about differences in efficacy of drugs by squamous or non-squamous, that’s the histology we’re talking about, the subtype of lung cancer. What we’ve seen over time is that there is a decline in incidence of squamous lung cancer and an increased incidence of adenocarcinoma. People have talked a lot about why this may be true — I think the dominant hypothesis is the advent of filters. Filters have not reduced lung cancer incidence but what they have done is bring the particulate matter further out to the periphery of the lung instead of larger particles that tend to settle more centrally in the lung. I think that’s probably what’s driving this change in incidence of squamous versus non-squamous histology.

GCVL_LU-A02b_LC_Demographics__Histology_06

There are some marked racial differences in presentation overall of lung cancer and by histology. The gist of this is that in terms of incidence there is increased incidence amongst black patients as compared to caucasian patients.

GCVL_LU-A02b_LC_Demographics__Histology_07

Presentation is also worse in black patients — there is a higher incidence of presentation at advanced stage, of course driving inferior outcomes and this is an important target for intervention.

Finally regardless of race, age and histology, I want to talk briefly about the thing that I hope will most change demographics in the years to come, and that’s screening.

GCVL_LU-A02b_LC_Demographics__Histology_08

Screening has the potential to catch lung cancer at an earlier stage and hopefully improve our cure rates regardless of any of the other factors we’ve talked about: histology, stage — well hopefully it’ll migrate the stage — race or gender. I think that when we talk about this in five or ten years, we’re going to be talking about much more favorable changes based on the results of screening, and so I would encourage screening for appropriate populations. We’ve done a number of other presentations on screening on cancerGRACE.org, and I refer you to those for more information.

Thank you.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Community Forum

Hi Carole, Welcome to Grace. If the adrenal is the only place that cancer has been seen since your lobectomy it could be that it's what's known as a precocious metastasis/oligoprogression...

Carole,

These approaches haven't been directly compared, and it really depends on who can do the job and what they say is appropriate to expect in terms of side effects. In...

Thank you so much I will call Monday and get your second opinion going. No ca anywhere else- lungs no change 2 years- but complicated by a gi bleed they cannot...

Hi CDaniele,
Welcome to Grace. If the TKI is working except for one or 2 places local treatment such as radiation can be used to get rid of the resistant cells...

I forgot to tell you that Grace is having its annual OncTalk live forum online Saturday, Dec. 11 at 8 am Pacific and 11 am Eastern
It will be invaluable to...

This is indeed a happy Thanksgiving in our house. I'll post about it at soon but we've just come out of a dark place and are feeling so hopeful today.
As...

Janine I am so happy to hear things like this. What you can or feel comfortable sharing, know that we are here! You are a very important part of the GRACE...

Recent Comments

JOIN THE CONVERSATION
Thank you so much I will…
By Carolesc on Sat, 12/04/2021 - 15:07
Carole,These approaches…
By Carolesc on Thu, 12/02/2021 - 20:49
Happy!
By dbrock on Thu, 12/02/2021 - 15:32
Hi Carole, Welcome to Grace…
By Carolesc on Thu, 12/02/2021 - 13:22